| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -154,440 | -129,323 |
| Stock-based compensation expense | 7,871 | 5,643 |
| Depreciation | 4,472 | 3,751 |
| Loss on disposal of fixed assets | -2,193 | -2,193 |
| Net accretion of discounts on marketable securities | 902 | 840 |
| Interest related to sale of future revenues | 6,635 | 4,236 |
| Impairment of held for sale assets | 3,724 | 3,724 |
| Other non-cash items | 390 | 390 |
| Accounts receivable | -8,136 | -15,678 |
| Prepaid expenses and other current assets | -175 | 418 |
| Right-of-use assets | -10,122 | -8,694 |
| Other non-current assets | -1,026 | -1,025 |
| Accounts payable | -2,330 | 1,231 |
| Accrued expenses | 1,728 | 2,271 |
| Accrued interest on sale of future revenues | -2,128 | -2,128 |
| Deferred revenue | -6,221 | -6,221 |
| Operating lease liabilities | -10,531 | -9,048 |
| Other non-current liabilities | 2,006 | 1,911 |
| Net cash used in operating activities | -128,854 | -98,011 |
| Purchases of property and equipment | 547 | 114 |
| Proceeds from the sale of equipment | 151 | 151 |
| Purchases of marketable securities | 0 | 0 |
| Proceeds from maturities of marketable securities | 139,006 | 99,000 |
| Net cash provided by investing activities | 138,610 | 99,037 |
| Repayment on sale of future revenues | 2,872 | 2,872 |
| Proceeds from issuance of common stock from at-the-market equity offering, net | 25,767 | 8,619 |
| Proceeds from exercise of stock options | 21 | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 228 | 228 |
| Net cash provided by financing activities | 23,144 | 5,975 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 32,900 | 7,001 |
| Cash and cash equivalents at beginning of period | 135,418 | - |
| Cash and cash equivalents at end of period | 168,318 | - |
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)